178 related articles for article (PubMed ID: 31866272)
21. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors.
Wang R; Yu S; Zhao X; Chen Y; Yang B; Wu T; Hao C; Zhao D; Cheng M
Eur J Med Chem; 2020 Feb; 188():112024. PubMed ID: 31923858
[TBL] [Abstract][Full Text] [Related]
22. Structure-based design and synthesis of 1H-pyrazolo[3,4-d]pyrimidin-4-amino derivatives as Janus kinase 3 inhibitors.
Yin Y; Chen CJ; Yu RN; Wang ZJ; Zhang TT; Zhang DY
Bioorg Med Chem; 2018 Sep; 26(17):4774-4786. PubMed ID: 30139575
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological evaluation of selenogefitinib for reducing bleomycin-induced pulmonary fibrosis.
Bai Y; Zhang Y; Chu P; Wang C; Li L; Qi Y; Han X; Zhang B; Sun H; Li Y; Chen L; Ma X
Bioorg Med Chem Lett; 2021 Sep; 48():128238. PubMed ID: 34216747
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor.
Elwood F; Witter DJ; Piesvaux J; Kraybill B; Bays N; Alpert C; Goldenblatt P; Qu Y; Ivanovska I; Lee HH; Chiu CS; Tang H; Scott ME; Deshmukh SV; Zielstorff M; Byford A; Chakravarthy K; Dorosh L; Rivkin A; Klappenbach J; Pan BS; Kariv I; Dinsmore C; Slipetz D; Dandliker PJ
J Pharmacol Exp Ther; 2017 May; 361(2):229-244. PubMed ID: 28193636
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects.
Overed-Sayer C; Miranda E; Dunmore R; Liarte Marin E; Beloki L; Rassl D; Parfrey H; Carruthers A; Chahboub A; Koch S; Güler-Gane G; Kuziora M; Lewis A; Murray L; May R; Clarke D
Thorax; 2020 Sep; 75(9):754-763. PubMed ID: 32709610
[TBL] [Abstract][Full Text] [Related]
26. Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors.
McDonnell ME; Bian H; Wrobel J; Smith GR; Liang S; Ma H; Reitz AB
Bioorg Med Chem Lett; 2014 Feb; 24(4):1116-21. PubMed ID: 24461299
[TBL] [Abstract][Full Text] [Related]
27. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
[TBL] [Abstract][Full Text] [Related]
28. Design and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes.
Gehringer M; Pfaffenrot E; Bauer S; Laufer SA
ChemMedChem; 2014 Feb; 9(2):277-81. PubMed ID: 24403205
[TBL] [Abstract][Full Text] [Related]
29. IL-17A contributes to HSV1 infection-induced acute lung injury in a mouse model of pulmonary fibrosis.
Chen T; Qiu H; Zhao MM; Chen SS; Wu Q; Zhou NY; Lu LQ; Song JC; Tang DL; Weng D; Li HP
J Cell Mol Med; 2019 Feb; 23(2):908-919. PubMed ID: 30378252
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, and biological evaluation of new pyrimidine-5-carbonitrile derivatives bearing 1,3-thiazole moiety as novel anti-inflammatory EGFR inhibitors with cardiac safety profile.
Abdel-Aziz SA; Taher ES; Lan P; Asaad GF; Gomaa HAM; El-Koussi NA; Youssif BGM
Bioorg Chem; 2021 Jun; 111():104890. PubMed ID: 33872924
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and SAR study of highly potent, selective, irreversible covalent JAK3 inhibitors.
He L; Shao M; Wang T; Lan T; Zhang C; Chen L
Mol Divers; 2018 May; 22(2):343-358. PubMed ID: 29411195
[TBL] [Abstract][Full Text] [Related]
32. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.
Mahajan S; Hogan JK; Shlyakhter D; Oh L; Salituro FG; Farmer L; Hoock TC
J Pharmacol Exp Ther; 2015 May; 353(2):405-14. PubMed ID: 25762693
[TBL] [Abstract][Full Text] [Related]
33. Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans.
Thorarensen A; Dowty ME; Banker ME; Juba B; Jussif J; Lin T; Vincent F; Czerwinski RM; Casimiro-Garcia A; Unwalla R; Trujillo JI; Liang S; Balbo P; Che Y; Gilbert AM; Brown MF; Hayward M; Montgomery J; Leung L; Yang X; Soucy S; Hegen M; Coe J; Langille J; Vajdos F; Chrencik J; Telliez JB
J Med Chem; 2017 Mar; 60(5):1971-1993. PubMed ID: 28139931
[TBL] [Abstract][Full Text] [Related]
34. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.
Telliez JB; Dowty ME; Wang L; Jussif J; Lin T; Li L; Moy E; Balbo P; Li W; Zhao Y; Crouse K; Dickinson C; Symanowicz P; Hegen M; Banker ME; Vincent F; Unwalla R; Liang S; Gilbert AM; Brown MF; Hayward M; Montgomery J; Yang X; Bauman J; Trujillo JI; Casimiro-Garcia A; Vajdos FF; Leung L; Geoghegan KF; Quazi A; Xuan D; Jones L; Hett E; Wright K; Clark JD; Thorarensen A
ACS Chem Biol; 2016 Dec; 11(12):3442-3451. PubMed ID: 27791347
[TBL] [Abstract][Full Text] [Related]
35. JAK3/STAT6 Stimulates Bone Marrow-Derived Fibroblast Activation in Renal Fibrosis.
Yan J; Zhang Z; Yang J; Mitch WE; Wang Y
J Am Soc Nephrol; 2015 Dec; 26(12):3060-71. PubMed ID: 26032813
[TBL] [Abstract][Full Text] [Related]
36. Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.
Ge Y; Wang C; Song S; Huang J; Liu Z; Li Y; Meng Q; Zhang J; Yao J; Liu K; Ma X; Sun X
Eur J Med Chem; 2018 Jan; 143():1847-1857. PubMed ID: 29146136
[TBL] [Abstract][Full Text] [Related]
37. Integrating network pharmacology, experimental validation and molecular docking to reveal the alleviation of Yinhuang granule on idiopathic pulmonary fibrosis.
Wu Z; Shi R; Yan S; Zhang S; Lu B; Huang Z; Ji L
Phytomedicine; 2024 Jun; 128():155368. PubMed ID: 38498951
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of CHIT1 as a novel therapeutic approach in idiopathic pulmonary fibrosis.
Sklepkiewicz P; Dymek BA; Mlacki M; Koralewski R; Mazur M; Nejman-Gryz P; Korur S; Zagozdzon A; Rymaszewska A; von der Thüsen JH; Siwińska AM; Güner NC; Cheda Ł; Paplinska-Goryca M; Proboszcz M; van den Bosch TPP; Górska K; Golab J; Kamiński RM; Krenke R; Golebiowski A; Dzwonek K; Dobrzanski P
Eur J Pharmacol; 2022 Mar; 919():174792. PubMed ID: 35122869
[TBL] [Abstract][Full Text] [Related]
39. Selective inhibitors of the Janus kinase Jak3--Are they effective?
Thoma G; Drückes P; Zerwes HG
Bioorg Med Chem Lett; 2014 Oct; 24(19):4617-4621. PubMed ID: 25217444
[TBL] [Abstract][Full Text] [Related]
40. Scaffold hopping towards potent and selective JAK3 inhibitors: discovery of novel C-5 substituted pyrrolopyrazines.
de Vicente J; Lemoine R; Bartlett M; Hermann JC; Hekmat-Nejad M; Henningsen R; Jin S; Kuglstatter A; Li H; Lovey AJ; Menke J; Niu L; Patel V; Petersen A; Setti L; Shao A; Tivitmahaisoon P; Vu MD; Soth M
Bioorg Med Chem Lett; 2014 Nov; 24(21):4969-75. PubMed ID: 25262541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
